Skip to main content
Smart Investors Daily
HL

NYSE · HLN

Haleon plc

Healthcare · Drug Manufacturers - Specialty & Generic

$9.08

Down-$0.03 (-0.33%)

Updated Nov 20, 2026, 1:56 AM

SID Score

5.6/10

Composite research score

Smart Money

56/100

Neutral

Market cap
43.5B
P/E ratio
21.41
Dividend yield
1.94%
52-week range
$8.38 – $11.28
Volume
19.46M
Avg. volume
11.03M

Price performance · HLN

HLN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 18, 2026

HLN closed at $9.08 after 20 trading sessions, down 12.44% for the selected period.

Last close
$9.08
Period change
-12.44%
Period low
$8.57
Period high
$10.37
Daily close
View OHLC price history
HLN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 18, 2026$9.06$9.13$9.04$9.0819.46M
Nov 17, 2026$9.11$9.16$9.05$9.0511.88M
Nov 16, 2026$9.31$9.335$9.19$9.2016.09M
Nov 13, 2026$9.13$9.22$9.11$9.1716.11M
Nov 12, 2026$9.16$9.185$9.06$9.0918.24M
Nov 11, 2026$9.00$9.14$8.98$9.1021.45M
Nov 10, 2026$9.03$9.08$8.97$9.0617.1M
Nov 9, 2026$9.09$9.09$8.925$8.9714.54M
Nov 6, 2026$8.91$9.15$8.88$9.1418.68M
Nov 5, 2026$9.23$9.36$9.09$9.1538.37M
Nov 4, 2026$9.04$9.27$9.00$9.2328.02M
Nov 3, 2026$8.87$8.9277$8.805$8.8431.98M
Nov 2, 2026$8.65$8.84$8.63$8.7634.94M
Oct 30, 2026$8.665$8.785$8.61$8.6632.53M
Oct 29, 2026$8.55$8.75$8.38$8.5756.76M
Oct 28, 2026$10.00$10.1076$9.965$10.0022.19M
Oct 27, 2026$10.13$10.15$10.0601$10.0815.86M
Oct 26, 2026$10.23$10.32$10.19$10.2015.27M
Oct 23, 2026$10.30$10.335$10.22$10.2715.07M
Oct 22, 2026$10.13$10.395$10.12$10.3714.62M

Latest HLN news

The latest Smart Investors Daily articles mentioning HLN.

HLN research

Overview

Company profile and research snapshot.

Company profile

Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$10.20
Implied upside
—
Analysts
5
HLN recent ratings
DateFirmRatingTarget
Jul 1, 2026DeutscheSell—
Jun 25, 2026JP Morgan CazenoveUnderweight—
May 5, 2026JefferiesBuy—
Apr 30, 2026Berenberg BankBuy—
Apr 30, 2026RBC Capital MarketsSector Perform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 13, 2026

Haleon (LSE:HLN) Stock Looks Reasonable Given Its Cash Flow Upside

Haleon has delivered a 10.0% share price gain over the past three years, yet the stock is still asking investors to judge whether that journey lines up with the cash it is expected to generate. The open question is whether the current valuation of Haleon stock can be explained by the stream of cash flows implied in its price today. That 10.0% return over three years puts real money on the line for anyone asking whether Haleon's current share price can be backed by the cash it is expected to...

Yahoo · Nov 10, 2026

Haleon (LSE:HLN) Stock Fair Value Falls After Guidance Cut And Mixed Analyst Revisions

Haleon’s analyst fair value estimate has changed, with the modelled price target moving from £4.18 to £3.76. This revision appears alongside a more mixed analyst narrative, where some research teams highlight execution risks and softer growth visibility, while others still point to the resilience of Haleon’s branded consumer health portfolio. As you read on, you will see how these changing targets fit into the broader story and what to watch as the Haleon narrative develops. Stay updated as...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.